David Stern Email & Phone Number

Boston, Ma, Us

From Lab to Launch, the AI Lab for Startups at D^3 helps Harvard academic-led innovations accelerate to have meaningful global impact. We accept only the most promising projects - teams that have deep technical expertise in their fields, commercializing new ventures born from research with AI/ML at the core of their innovation.

Freya Biosciences is a trans-Atlantic biotech company specializing in women's health. With a focus on reproductive microbial immunotherapy interventions, Freya aims to improve fertility outcomes and empower women with innovative solutions.

Lafayette, California, Us

Boulder, Colorado, Us

Waltham, Massachusetts, Us

Provide commercialization strategy and business operational support to several well respected pharma/biotech/life science organizations/startups. Specializing in marketing strategy, managed care access differentiation, key opinion leader development, business development and strategy, clinical trial design for label claims, and market analysis.

Cambridge, Massachusetts, Us

Los Angeles, Ca, Us

California Cryobank is the leading provider of reproductive and stem cell services in the United States. California Cryobank was sold to GI Partners in 2018. Provide strategic guidance for company on long term goals; set annual, 3 year revenue and EBITA targets.  Chair of compensation committee. Approve all executive salaries and bonus plans. Assist in company growth through international opportunities and M&A strategy.

Symbiomix Therapeutics was an Orbimed/F-Prime Capital Partners backed biopharmaceutical company that brought innovative medicines to market for prevalent gynecologic infections that can have serious health consequences. Solosec, the company's first drug was approved by the FDA as the first and only single dose treatment for bacterial vaginosis in September 2017. Successfully sold Symbiomix to Lupin Pharmaceuticals in October 2017 Build capabilities for commercial launch of SolosecTM to OBGYNs in the US. Identify third party logistics partner; license company in 31 states; negotiate wholesaler contracts; develop market access strategy; contract with managed care organizations. Responsible for corporate strategy and business planning, capital structure and fundraising, business development strategy, Phase 4, lifecycle management and pipeline development. Present at financial conferences, secure funding, and meet with potential investors.  Board member and facilitator of quarterly Board of Managers meetings; ensure alignment between board and company management.

New York, Ny, Us

Celmatix is a privately held precision medicine company focused on maximizing lifelong female fertility. I am responsible for developing and executing the company’s go-to-market strategies for Polaris, the world's first analytics platform that helps fertility doctors create personalized treatment plans designed to maximize a woman's fertility, among other products. Develop launch strategy for positioning and messaging, marketing, sales pricing and business model of Polaris US launch. Identify, develop, and build research continuum of Key Opinion Leaders within the Fertility Industry to compile clinical experience. Assemble commercial team consisting of sales, marketing and customer support for launch. Develop and execute strategy for the annual European Society of Human Reproductive Endocrinology and American Society of Reproductive Medicine congresses.  Identify thought leaders and develop relationships with advisory board members. Member of Celmatix executive team, guiding long term strategy development.

Head of Global Commercial, preparing to launch new innovative fertility treatment to help improve egg quality for women that have failed multiple IVF cycles or have poor egg quality.Develop global strategy and launch company’s first commercial treatment. Create launch strategy for positioning and messaging, marketing, sales, and go-to-market distribution. Launch first commercial treatment, AUGMENT, in four regions outside of the US. Identify and initiate Center of Excellence model of Key Opinion Leaders within Fertility Industry to compile clinical experience. Build commercial team consisting of sales, marketing and medical personnel. Develop and execute global strategy for the annual global congresses.  Member of OvaScience executive team, participating in long term strategy development.

Darmstadt, Hessen, De

Maximize long-term franchise value and ensure business sustainability. Head of Global Franchise Team comprised of Regional Business Franchise Leaders, Top 10 country Business Unit Heads (EU5, US, China, Japan, Australia, Russia), Business Development, Portfolio Management, Medical Affairs, R&D, Business Intelligence, Finance, and Manufacturing. Responsible for short, mid and long term strategic development and growth of $1 Billion Global Fertility Portfolio consisting of 7 global brands.  Shape the Global Franchise Strategy and develop global ten-year Strategic Plan for long term Franchise sales and P&L.  Build pipeline through collaborative external research model. Developed new R&D model with external partners to create 19 new projects for “high speed” clinical validation of new technologies to improve overall patient outcomes. Lead Business Development in acquiring new technologies for vertical integration into Assisted Reproductive Technologies. o Closed deal with Auxogyn to provide strategic, medical, and commercial support for launch of Eeva™ Embryo Diagnostic Test.

Boston, Massachusetts, Us

Head of Commercial US Operations for Fertility, Growth Hormone, and HIV Responsible for US Commercial Operations for EMD Serono Core Product Portfolio in Reproductive Health and Metabolic Endocrinology. Full P&L responsibility, demonstrated ability to drive revenue while maintaining high margins.o Gonal-f®, Ovidrel®, Luveris®, Cetrotide®,– Reproductive Portfolioo Egrifta®, Saizen®, Serostim®, Zorbtive® – Metabolic Endocrinology Built a commercial infrastructure that turned lagging Fertility business around, gained back $50M of lost sales revenue, grew share by 7% in 2007, 13.5% in 2008.  Gonal-f named 2007 Brand of the Year.  Serostim named 2008 Brand of the Year following 3rd year in a row of surpassing revenue & unit growth targets in HIV. Lead and motivate a business unit with 130 professionals to deliver double-digit top-line revenue growth while managing expenses to generate positive margins. Oversee partner relationship with development partner, Theratechnologies in launching new drug class for HIV Lipodystrophy in US market, EGRIFTA®. Present quarterly to US President, Global COO and Global CEO.  Member of the US Senior Team.

Boston, Massachusetts, Us

Responsible for the commercial operations of the Metabolic Endocrinology Business Unit in the US, Including Marketing, Medical, Sales, Business Development.

Boston, Massachusetts, Us

Jersey City, Nj, Us

 Create strategy and manage launch of the first Direct-To-Consumer campaign, NuvaRing. Total revenue of Therapeutic area - $350 million (2002). P&L responsibility for $58 million dollar marketing budget for Women’s Health Franchise.  Responsible for Business Development for Women’s Health Portfolio including in-license, co-marketing, and out-license agreements.

Mba, International Marketing And Management

Ba, Biology And Economics

Education record